Neoadjuvant flutamide monotherapy for locally confined prostate cancer

International Journal of Urology

Volumn 10, Issue 4, 2003, Pages 190-195

  Yoshimura, Koji ^a   Sumiyoshi, Yoshiteru ^b   Hashimura, Takayuki ^c   Ueda, Tomohiro ^d   Kamiryo, Yoriaki ^e   Yamamoto, Akihiro ^f   Arai, Yoichi ^g  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION HIMEJI MEDICAL CENTER   (Japan)

^d Kouga Public Hospital   (Japan)

^e Saiseikai Shimonoseki General Hospital   (Japan)

^f Kochi Takasu Hospital   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiandrogen; Neoadjuvant hormone therapy; Prostate cancer; Quality of life

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRIN; ODYNE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; ECZEMA; FOLLOW UP; GYNECOMASTIA; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HUMAN TISSUE; LIBIDO; LIVER TOXICITY; MALE; MASTALGIA; MONOTHERAPY; ORGAN SIZE; OUTCOMES RESEARCH; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL FUNCTION; SKIN ALLERGY; SURVIVAL RATE; TESTOSTERONE BLOOD LEVEL;

AGED; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; FERTILITY AGENTS, FEMALE; FLUTAMIDE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; TESTOSTERONE; TREATMENT OUTCOME;

EID: 0037809297     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0919-8172.2003.00601.x     Document Type: Article

References (28)

1. Labrie F, Dupont A, Cusan L et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin. Invest. Med. 1993; 16: 499-509.
2. Goldenberg SL, Klotz LH, Srigley J et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J. Urol. 1996; 165: 873-7.
3. Schulman CC, Wildshutz T, Zlotta AR. Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions. Eur. Urol. 1997; 32: 41-7.
4. Fair W, Cookson MS, Stroumbakis N et al. The indications, rationale and results ofneoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997; 49 (Suppl. 3A): 46-55.
5. Aus G, Abrahamsson PA, Ahlgren G et al. Hormonal treatment before radical prostatectomy: a 3-year follow-up. J. Urol. 1998; 159: 2013-7.
6. Lee HH, Warde P, Jewett MAS. Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int. 1999; 83: 438-48.
7. Schulman CC, Debruyne FMJ, Forster G et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur. Urol. 2000; 38: 706-13.
8. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol. 1996; 155: 213-9.
9. van der Kwast TH, Tetu B, Candas B, Gomez JL, Cusan L, Labrie F. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology 1999; 53: 523-9.
10. Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 2000; 56: 289-94.
11. Gleave ME, Goldenberg L, Chin JL et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J. Urol. 2001; 166: 500-7.
12. Brogden RN, Clissold SP. Flutamide. a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs 1989; 38: 185-203.
13. Fossa SD, Aaronson NK, Newling D et al. and the EORTC Genito-Urinary Group. Quality of life and treatment of hormone resistant metastatic prostatic cancer. Eur. J. Cancer 1990; 26: 1133-6.
14. Isaka S, Shimazaki J, Akaza H et al. Assessment of the quality of life of prostate cancer patients. Nippon Hinyokika Gakkai Zasshi 1993; 84: 1611-7.
15. Kato R, Sato Y, Horita H et al. Validity analysis of Sapporo Medical University: sexual function questionnaire. Nippon Hinyokika Gakkai Zasshi 1999; 90: 872-7.
16. Arai Y, Aoki Y, Okubo K et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J. Urol. 2000; 164: 1206-11.
17. Kuriyama M, Akimoto S, Akaza H et al. Comparison of various assay systems for prostate-specific antigen standardization. Jpn. J. Clin. Oncol. 1992; 22: 393-9.
18. Japanese Urological Association the Japanese Pathological Society. General Rule for Clinical and Pathological Studies on Prostate Cancer, 2nd edn. Kanahara Publication, Tokyo, 1992; 90-1.
19. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication, Geneva, 1979; 14-21.
20. Iversen P. Quality of life issues relating to endocrine treatment options. Eur. Urol. 1999; 36 (Suppl. 2): 20-6.
21. Zincke H, Bergstrahl EJ, Larsson-Keller JJ et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: evidence for favorable survival in patients with DNA diploid tumors. Cancer 1992; 70 (Suppl. 1): 311-23.
22. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990; 50: 2275-82.
23. Boccardo F, Rubagotti A, Barichello M et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian prostate cancer project study. J. Clin. Oncol. 1999; 17: 2027-38.
24. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J. Urol. 2000; 164: 1579-82.
25. Kolvenbag GJ, Iversen P, Newling DW. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology 2001; 58 (Suppl. 2A): 16-23.
26. Chang A, Yeap B, Davis T et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J. Clin. Oncol. 1996; 14: 2250-7.
27. Boccon-Gibod L, Fournier G, Bottet P et al. Flutamide versus orchidectomy in patients with metastatic prostate carcinoma. Eur. Urol. 1997; 32: 391-5.
28. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J. Urol. 1996; 155: 209-12.